VolitionRx Limited announced that the company is expanding into the Asian markets with the appointment of Dr. Jasmine Kway as Vice President of Asia. This geographic expansion follows on from Volition's recent announcement that the company's first blood-based diagnostic cancer test, the Nu.QTM Colorectal Cancer Triage Test, has achieved a CE mark, allowing for its sale in all 28 EU countries. Volition plans to bring the product to market in Europe this year and will be working with Dr. Kway to expand into the Asian markets with direct marketing to countries with screening programs as well as seeking the required approvals for use in the new Asian markets. Prior to joining Volition, Dr. Kway served as Chief Executive Officer of IP practice at RHT i-Assets Advisory.